Preview Mode Links will not work in preview mode

Sep 25, 2019

Chronic Lymphocytic Lymphoma, Issue 2, 2019 — Part 2: Our interview with Dr Woyach highlights the following topics as well as cases from her practice:

  • Recent data and evolution of the front-line treatment paradigm for patients with CLL (00:00)
  • Evaluation of MRD and implications for therapy (03:50)
  • Efficacy and tolerability of first-line regimens for CLL (06:14)
  • Perspective on the role of chemoimmunotherapy for patients with CLL (08:41)
  • Case: A woman in her mid-70s experiences a dramatic response after receiving ibrutinib as first-line therapy for CLL (10:48)
  • Bleeding and arthralgias associated with ibrutinib (12:14)
  • Rates of discontinuation and the role of dose reduction to mitigate side effects in patients receiving ibrutinib (14:45)
  • Incidence and management of opportunistic infections during ibrutinib treatment (18:11)
  • Role of chimeric antigen receptor (CAR) T-cell therapy in CLL; effect of ibrutinib on CAR T-cell generation and efficacy (21:54)
  • Case: A man in his late 60s with CLL receives acalabrutinib on a clinical trial after developing atrial fibrillation on ibrutinib therapy (24:01)
  • Therapeutic approach for patients who develop resistance to BTK inhibitors (27:19)
  • Understanding the C481S mutation as a mechanism of resistance to ibrutinib and acalabrutinib (30:47)
  • Targeting the C481S mutation to overcome resistance to BTK inhibitors (32:06)
  • Case: A woman in her mid-60s with del(17p) CLL and no IGHV mutation receives venetoclax after disease progression on multiple lines of therapy (36:11)
  • Prophylactic measures to prevent venetoclax-associated tumor lysis syndrome (38:25)
  • Emerging data with the combination of ibrutinib and venetoclax for CLL (40:04)
  • Activity and tolerability of PI3 kinase inhibitors for patients with CLL (44:17)
  • Acalabrutinib with obinutuzumab for treatment-naïve and relapsed/refractory CLL (47:51)
  • Incidence and spectrum of second cancers among patients with CLL receiving BTK inhibitors (49:51)
  • Case: A man in his early 70s develops RT to DLBCL after receiving ibrutinib as first-line therapy for CLL (51:00)
  • Prognosis and management of RT (53:38)
  • Role of immune checkpoint inhibitors and CAR T-cell therapy in the management of RT (56:37)
  • Ongoing Phase III EA9161 and Alliance A041702 studies evaluating the addition of venetoclax to ibrutinib with obinutuzumab for patients with CLL (59:21)

CME information and select publications